



IFW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Saeed R. Khan *et al.*) Group Art Unit: 1645
Serial No.: 10/627,991) Examiner: TBA
Filed: July 28, 2003) Attorney Docket No. 001107.00371
For: DESIGN AND SYNTHESIS OF RENAL)
DIPEPTIDASE INHIBITORS)

INFORMATION DISCLOSURE STATEMENT
37 C.F.R. § 1.97(e)(1)

Commissioner for Patents
Post Office Box 1450
Alexandria, Virginia 22313-1450


Submitted herewith is one (1) sheet of Form PTO-1449. A copy of the cited reference is enclosed. It is respectfully requested that the Examiner make his/her consideration of this document formally of record.

This Information Disclosure Statement is filed pursuant to 37 C.F.R. § 1.97 (e)(1). The undersigned certifies that the item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and that this communication was not received by the undersigned more than thirty days prior to the filing of this Information Disclosure Statement. It is believed that no fee is required to ensure consideration of the cited references by the Examiner. However, if a fee is deemed necessary, the Commissioner is authorized to charge Deposit Account 19-0733.

Respectfully submitted,

Dated: June 4, 2004

By:


Sarah A. Kagan
Registration No. 32,141

Banner & Witcoff, Ltd.
Customer No. 22907

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/627,991
Filing Date	July 28, 2003
First Named Inventor	Saeed R. Khan
Group Art Unit	1645
Examiner Name	TBD

Attorney Docket Number

001107.00371

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Accession No: 2003:114414. Tetrahedron Letters, 2003 Gurulingappa, Hallur et al., Design, synthesis and evaluation of new RDP inhibitors listed in Tetrahedron Letters (2003), Vol. 44, No. 9, abstract	

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231